Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece (FIDELITY)
A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study
Sponsor: Genesis Pharma CNS & Specialty
Listed as NCT03101735, this observational or N/A phase trial focuses on RRMS and remains completed. Sponsored by Genesis Pharma CNS & Specialty, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting
▶ Show 4 earlier versions
-
Aug 2018 — Mar 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genesis Pharma CNS & Specialty
For direct contact, visit the study record on ClinicalTrials.gov .